Supplementary Tables S5–S14 show the unfiltered and unranked MHC Class I and II epitope/HLA pairs by cancer subtype. Supplementary Tables S15 and S16 detail the final lists of predicted immunogenic Class I and II epitopes by point mutation, respectively. Table 6 presents an overview of the number of point mutations that generated MHC Class I and II immunogenic epitopes. Certain point mutations led to the generation of both Class I and Class II epitopes, indicating that vaccines incorporating these epitopes may elicit both CD8+ and CD4+ T-cell responses in patients. This evidence concerns the gene CD8A and cancer.